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Running Head: cIMPACT-7 ependymal tumors
Ependymal tumors make up a heterogeneous category of central nervous system (CNS) gliomas 
with variably expressed morphologic, immunophenotypic, and ultrastructural ependymal features 
(9). The current WHO classification (2016) lists: subependymoma (WHO grade 1), myxopapillary 
ependymoma (WHO grade 1), the classic ependymoma with its three histological subtypes – 
papillary, clear cell, and tanycytic (WHO grade 2), anaplastic ependymoma (WHO grade 3), and 
one genetically defined type – ependymoma, RELA fusion-positive (WHO grade 2 / 3). However, 
aspects of this scheme are not ideal; for example, in some clinical settings, there is a poor 
association between tumor grading and outcome (4). In addition, recent studies using DNA 
methylation profiling to demonstrate molecular groups of ependymoma and genome-wide 
sequencing to determine the genomic landscape of the disease support the proposition that 
ependymomas with similar morphologic features from across the neuraxis have distinct origins 
and oncogenic events of clinicopathologic significance and potential therapeutic utility (12, 14, 15, 
17). Seeking to improve the current classification, cIMPACT working committee 2 (WC2) 
considered a scheme based around molecularly defined types of ependymoma. 
Background to the molecular classification of ependymoma
Methylation and gene expression profiling studies have provided evidence for at least nine 
molecular groups of ependymoma across the three principal anatomic compartments of the CNS: 
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groups have distinct molecular alterations and clinicopathologic characteristics, and their 
identification has clinical utility. 
One molecular group at each anatomic site consists almost entirely of tumors with the 
morphologic features of subependymoma (15). Of the two remaining ST molecular groups, one 
is dominated by ependymomas with C11orf95-RELA fusion genes, and the other contains tumors 
with a high frequency of YAP1-MAMLD1 fusions (1, 17). Occasionally, other fusion genes are 
present in ST ependymomas; for example, C11orf95 has been reported to partner with MAML2 
and YAP1, and YAP1 with FAM118B. In addition, some ST ependymomas have no detectable 
fusion gene and rare ependymomas with C11orf95-RELA fusions arise in the PF (DWE & KDA – 
personal observations). Across reported datasets, C11orf95 and YAP1 contribute most often to 
pathogenic fusions in the ST-RELA and ST-YAP1 molecular groups, respectively. These two 
groups of ST ependymoma are distinguished by their clinical characteristics. However, while a 
difference in patient outcome was reported for the ST-RELA and ST-YAP1 groups in one 
retrospective study (15), RELA fusion status was not found to be prognostic in another trial-based 
study (13). The clinical significance of rare genetic fusion events in ST ependymomas remains 
unclear.
Unlike ST ependymomas, PF ependymomas lack recurrent mutations (12, 17). However, 
methylation profiling divides them into two main groups, PFA and PFB, which are also 
distinguished by global levels of histone H3 K27-trimethylation (16). This epigenetic mark is high 
in PFB ependymomas, but low in PFA tumors. PFA ependymomas occur mainly in infants, while 
PFB tumors arise mainly in older children and adults. Patient outcome might also be different; 
most, but not all, studies show that PFA ependymomas have a significantly worse prognosis (13, 
15, 16, 21, 23). 
Among SC ependymomas are the myxopapillary tumors that predominate in adult patients. These 
form one methylation group; classic ependymomas form a second, and a rare third group consists 
of spinal subependymomas. Recently, an aggressive SC ependymoma characterized by early 
dissemination throughout the neuraxis, an anaplastic morphology, and MYCN amplification has 
been reported (5, 19). Other data indicate that, in adults, classic ependymomas and myxopapillary 
ependymomas have a similar outcome, suggesting that the latter might be more appropriately 
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For subependymomas and myxopapillary ependymomas, the relationship between morphology 
and methylome group is imprecise. Some classic ependymomas without anaplastic features fall 
into the subependymoma or myxopapillary ependymoma molecular group (22). In addition, the 
clinical relevance of such findings is unclear; as yet, there is no indication that classification by 
molecular group provides more clinical utility than the current morphologic classification of these 
two tumor types. 
The above findings have provided impetus to update the classification of ependymomas and, 
alongside other datasets, have prompted a series of recommendations from cIMPACT WC2: 
 Ependymomas should be classified by anatomic site and by molecular group or an 
associated genetic alteration, so that classification of the disease reflects its underlying 
biology. 
 ST ependymomas should be classified according to the genes, C11orf95 and YAP1, that 
contribute to most pathogenic gene fusions in each of the two major molecular groups. 
 PF ependymomas should be classified according to the two most prevalent molecular 
groups, PFA and PFB. 
 SC ependymomas with MYCN amplification should be recognized as a distinctive type of 
ependymoma with a poor outcome. 
 Meaningful data related to the outcome of patients on clinical trials are not yet available 
for a WHO grade to be assigned to types of ependymoma defined by molecular alterations. 
 The rare subependymoma should continue to be identified by morphologic criteria; no 
clear clinical utility is yet attached to the identification of a subependymoma molecular 
group at each anatomic site. 
 SC myxopapillary ependymomas should continue to be identified by morphologic criteria 
but designated WHO grade 2, because clinical trial datasets do not support a WHO grade 
1 clinical behavior.  
 Morphologic subtypes of the classic ependymoma (papillary, clear cell, tanycytic) should 
be recognized as distinctive patterns in the histopathological description of 
ependymomas; but, affording no specific clinical utility, they should no longer be included 
in the classification of the disease. 
These recommendations were used to produce a novel classification of ependymal tumors 
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made on morphologic criteria. Other ependymomas would be classified according to anatomic 
site and the results of molecular testing, if available. If molecular testing has been undertaken, 
yet no result generated to place an ependymoma among the molecularly defined tumor types in 
the classification, then the histologically defined diagnosis ‘ependymoma’ is used with the suffix 
‘NEC’ (not elsewhere classified). When molecular testing is unavailable, then ‘ependymoma’ is 
used with the suffix ‘NOS’ (not otherwise specified) (11). 
Practical aspects of classifying ependymomas
Longstanding controversy surrounds the clinicopathological utility of grading ependymal tumors 
(4); though use of WHO grade in the therapeutic stratification of adult patients with ST 
ependymoma remains established practice (20). Our proposed classification allows only a 
histologically defined diagnosis of ‘ependymoma’ to be made at any of the three anatomic sites. 
However, in the upcoming edition of the WHO classification, several tumor types can be assigned 
to more than one grade, including ependymal tumors. As currently for the ependymoma, RELA 
fusion-positive, a pathologist will be able to assign either grade 2 or grade 3 to an ependymoma 
defined by morphologic criteria (Table), and in a change from previous editions of the 
classification anaplastic ependymoma will not be listed. 
A range of diagnostic tests can be used to discover molecular alterations that define the new 
types of ependymoma. Sequencing might demonstrate the fusion genes of the two types of ST 
ependymoma, and interphase fluorescence in situ hybridization (iFISH) to demonstrate 
rearrangement of C11orf95, RELA, or YAP1 can support the presence of a fusion gene (17). 
iFISH can also show the defining amplification of the spinal ependymoma, MYCN-amplified. 
Immunohistochemistry to assess the expression of H3 K27-trimethylation can be used to 
distinguish PFA and PFB ependymomas (16). 
DNA methylation profiling is proving to be a powerful tool for the classification of CNS tumors; it 
works with formalin-fixed paraffin-embedded derivatives and can provide a diagnosis from small 
tissue samples (2). It is also a powerful adjunct when histopathological features converge on more 
than one possible diagnosis. For example, the histopathology of ST ependymomas overlaps with 
several tumor types that were originally identified by methylation profiling, especially the CNS 
high-grade neuroepithelial tumor with MN1 alteration (18). Because of its ability to determine 
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classified as an ependymoma or whether a PF ependymoma falls into the PFA or PFB molecular 
group, WC2 proposes consideration of methylation profiling as a front-line diagnostic test when 
ependymoma is part of the histopathological differential diagnosis. 
WC2 considered chromosome 1q gain as a molecular marker to be used in the classification of 
PF ependymomas. Gain of 1q is present in 15-20% of PF ependymomas and has been reliably 
and reproducibly associated with a poor outcome and pattern of progression among patients with 
these tumors (6-8, 13). However, among nine subtypes of PFA ependymoma discovered by 
methylation profiling, outcome was highly variable, and subtypes with a poor prognosis could be 
enriched for 1q gain (subtype PFA-1c) or not (subtype PFA-1e) (14). Considering these data, 
WC2 proposes that reference to 1q status is placed in the integrated diagnosis among other 
molecular information (10), rather than used to define a tumor type in the classification. 
In conclusion, WC2 proposes a classification of ependymal tumors that extends the principle of 
defining CNS tumors by characteristic molecular alterations. An integrated and tiered approach 
to reporting the diagnosis is recommended for capturing information on molecular characteristics 
alongside histopathological features. 
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